<?xml version="1.0" encoding="UTF-8"?>
<p>The typical locomotion tracking pattern (
 <xref ref-type="fig" rid="antioxidants-09-01083-f003">Figure 3</xref>A) illustrates the differences in swimming traces among the Y-maze arms. Sco-exposed zebrafish explored the novel arm less, suggesting deficits in the response to novelty. In the Y-maze test, one-way ANOVA revealed significant effect of the treatment on the time spent in each arm (F (8.90) = 19.60, 
 <italic>p</italic> &lt; 0.0001) (
 <xref ref-type="fig" rid="antioxidants-09-01083-f003">Figure 3</xref>B), on the total distance traveled (F (4.45) = 12.47, 
 <italic>p</italic> &lt; 0.0001) (
 <xref ref-type="fig" rid="antioxidants-09-01083-f003">Figure 3</xref>C), the turn angle (F (4.45) = 3.53, 
 <italic>p</italic> &lt; 0.01) (
 <xref ref-type="fig" rid="antioxidants-09-01083-f003">Figure 3</xref>D) and the preference percentages (F (4.45) = 25.36, 
 <italic>p</italic> &lt; 0.0001) (
 <xref ref-type="fig" rid="antioxidants-09-01083-f003">Figure 3</xref>E). Sco administration decreased the time spent in the novel arm (
 <italic>p</italic> &lt; 0.0001) (
 <xref ref-type="fig" rid="antioxidants-09-01083-f003">Figure 3</xref>B) as compared with the control group, suggesting memory impairment. Besides, Sco treatment-induced hypolocomotion as evidenced by a decrease of the total distance traveled (
 <italic>p</italic> &lt; 0.0001) (
 <xref ref-type="fig" rid="antioxidants-09-01083-f003">Figure 3</xref>C) and the turn angle (
 <italic>p</italic> &lt; 0.001) (
 <xref ref-type="fig" rid="antioxidants-09-01083-f003">Figure 3</xref>D), as compared with the control group. TEO significantly improved memory deficits as evidenced by an increase of the time spent in the novel arm, in a dose-dependent manner (
 <italic>p</italic> &lt; 0.001 for 25 μL/L and 
 <italic>p</italic> &lt; 0.0001 for 150 μL/L and 300 μL/L) (
 <xref ref-type="fig" rid="antioxidants-09-01083-f003">Figure 3</xref>B), as compared to Sco-alone treated fish. Moreover, TEO prevented Sco-induced hypolocomotion by significantly increased the total distance traveled in the tank (
 <italic>p</italic> &lt; 0.001) (
 <xref ref-type="fig" rid="antioxidants-09-01083-f003">Figure 3</xref>C). Control group showed preferences for the novel arm in the Y-maze test, while Sco-treated zebrafish displayed less percentage preferences for the novel arm (
 <italic>p</italic> &lt; 0.0001) (
 <xref ref-type="fig" rid="antioxidants-09-01083-f003">Figure 3</xref>E) as compared to control group, suggesting an impaired response to novelty. Besides, administration of TEO (25, 150, and 300 μL/L) in the Sco-treated animals, significantly improved the preference percentages (
 <italic>p</italic> &lt; 0.0001 for 25, 150, and 300 μL/L) suggesting memory-enhancing profile (
 <xref ref-type="fig" rid="antioxidants-09-01083-f003">Figure 3</xref>E). Furtheremore, the preference percentage in control (t = 21.21, 
 <italic>p</italic> &lt; 0.0001), Sco (t = 9.13, 
 <italic>p</italic> &lt; 0.0001), TEO (25 µL/L) + Sco (t = 21.86, 
 <italic>p</italic> &lt; 0.0001), TEO (150 µL/L) + Sco (t = 11.98, 
 <italic>p</italic> &lt; 0.0001), and TEO (300 µL/L) + Sco (t = 25.59, 
 <italic>p</italic> &lt; 0.0001) groups were statistically different from the chance level (50%) (
 <xref ref-type="fig" rid="antioxidants-09-01083-f003">Figure 3</xref>E).
</p>
